Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed-duration IMBRUVICA ® (ibrutinib) plus venetoclax as first-line treatment for patients with chronic lymphocytic leukaemia, including those with high-risk disease
At 5 years, 67 percent of patients were progression-free, with overall survival at 96 percent for all treated patients
1
BEERSE, BELGIUM (14 June 2024)
– Janssen-Cilag International NV, a Johnson & Johnson company, today announced updated findings...
Zur Pressemeldung auf www.jnj.com